Case Report/Case Series
July 2013

Inadvertent Implantation of Aqueous Tube Shunts in Glaucomatous Eyes With Unrecognized Intraocular Neoplasms: Report of 5 Cases

Author Affiliations
  • 1Department of Ophthalmic Pathology, Wills Eye Institute, Thomas Jefferson University, Philadelphia, Pennsylvania (Drs Kaliki and Eagle)
  • 2Ocular Oncology Service, Wills Eye Institute, Thomas Jefferson University, Philadelphia, Pennsylvania (Drs Kaliki, C. L. Shields, and J. A. Shields)
  • 3Ocular Oncology Service, L. V. Prasad Eye Institute, Hyderabad, India (Dr Kaliki)
  • 4Department of Ophthalmology, Emory University, Atlanta, Georgia (Dr Grossniklaus)
  • 5Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota (Dr Campbell)

Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Ophthalmol. 2013;131(7):925-928. doi:10.1001/jamaophthalmol.2013.828

Intraocular tumors are a recognized cause of secondary glaucoma. Mechanisms of tumor-related glaucoma include direct tumor invasion or infiltration of the anterior chamber angle, pupillary block caused by anterior displacement of iris-lens diaphragm in the eyes with tumors located posterior to the iris, melanomalytic or melanocytomalytic glaucoma, tumor-induced neovascular glaucoma, inflammatory glaucoma secondary to tumor necrosis, hemolytic glaucoma, and glaucoma due to elevated episcleral venous pressure secondary to extraocular tumor extension.1 A survey of 2704 eyes with intraocular tumors revealed tumor-related glaucoma in 126 eyes (5%) including uveal melanoma (55 of 2111 [3%]), uveal metastases (12 of 256 [5%]), retinoblastoma (51 of 303 [17%]), intraocular lymphoma (3 of 11 [27%]), intraocular leukemia (1 of 11 [9%]), ciliary body medulloepithelioma (2 of 2 [100%]), iris melanocytoma (1 of 1 [100%]), and iris pigment epithelial adenoma (1 of 2 [50%]).1

First Page Preview View Large
First page PDF preview
First page PDF preview